Archive
Here you can find the archive of all Press Releases prior to 2018
Filter by date:
Showing 676 press releases before 2019
-
AstraZeneca and Bristol-Myers Squibb announce US FDA approval of FARXIGA™ (dapagliflozin)
-
AstraZeneca and Shionogi settle arbitration and extend licence agreement for CRESTOR®
-
AstraZeneca to acquire Bristol-Myers Squibb share of global diabetes alliance assets
-
AstraZeneca statement in response to reports of a launch of esomeprazole strontium product in the US
-
AstraZeneca announces top-line results from phase III monotherapy study of lesinurad in gout patients
-
FDA Advisory Committee votes on investigational medicine metreleptin
-
FDA Advisory Committee recommends the investigational SGLT2 inhibitor dapagliflozin for treatment of type 2 diabetes in adults
-
AstraZeneca donates Brixham Environmental Laboratory to Plymouth University
-
European Commission approves Fluenz Tetra for the prevention of seasonal influenza in children
-
AstraZeneca awarded damages in Prilosec® patent litigation
Latest articles and press releases
All of our latest press releases and articles are available to explore
Contact us
Email the Global Media Relations team at:
Gonzalo Viña
Head of Global Media Relations
+44 (0)1223 344 800
Kim Blomley
Director Global Media Relations (Oncology)
+44 (0)1223 344 800
Matthew Kent
Director Global Media Relations (BioPharmaceuticals)
+44 (0)1223 344 800
Angela Fiorin
Director Global Media Relations (BioPharmaceuticals)
+44 (0)1223 344 800
Fiona Cookson
Director Global Media Relations (Covid-19)
+44 (0)1223 344 800
Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
+46 855 253 106
